Fortrea Holdings (NASDAQ:FTRE) 주식

FORTREA HOLDINGS INC

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

WallStreet.NYSE

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

월요일 아침 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 먼데이닷컴(NASDAQ:MNDY)이 개장 전 2억 2,877만 달러의 매출과 주당 56센트의 분기 이익을 보고할 것으로 예상하고 있다. 먼데이닷컴의 주가는 시간외 거래에서 1% 상승한 228.00달러를 기록했다.

월요일 주목해야 할 주식: 먼데이닷컴, 선 라이프 파이낸셜 그리고  3종목

Fortrea Holdings Inc

Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 75.57 percent increase over losses of $(1.31) per share from the same period last year.

Earnings

Earnings Beats

BBLG

Bone Biologics Q1 EPS $(0.32) Beats $(0.48) Estimate

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 Sales $85.17M Up From $50.23M YoY

Barclays analyst Theresa Chen maintains MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) with a Overweight and lowers the price target from $55 to $52.

Price Target

Analyst Ratings

MPLX

Barclays Maintains Overweight on MPLX, Lowers Price Target to $52

Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.41) by 36.59 percent. This is a 92.95 percent increase over losses of $(3.69) per share from the same period last year.

GNPX

Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Equal-Weight and lowers the price target from $60 to $57.

Barclays Maintains Equal-Weight on Molson Coors Beverage, Lowers Price Target to $57

Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.70) by 32.86 percent. This is a 89.76 percent increase over losses of $(4.59) per share from the same period last year.

PALI

Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Getty Images Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) reported first-quarter financial results Monday after the close. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/g45359438/getty-images-reports-first-quarter-2025-results">from the print</a>.
Q1 Earnings: Getty Images reported first-quarter revenue of $224.08 million, missing analyst <a href="http://benzinga.com/quote/gety/estimates">estimates</a> of $236.01 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of 14 cents per share.
Total revenue was up 0.8% year-over-year and annual subscription revenue climbed 5.4% year-over-year. Here&#8217;s a breakdown of revenue by category:
<ul class="wp-block-list">
<li>Creative revenue: $132.3 million, down 4.8%</li>
</ul>
<ul class="wp-block-list">
<li>Editorial revenue: $82.6 million, up 4% </li>
</ul>
Getty Images generated cash flow from operations of $15.4 million and reported negative free cash flow of $300,000. The company ended the quarter with $114.6 million in cash.
&#8220;Results in the&nbsp;first quarter&nbsp;were consistent with our expectations, with growth highlighted by gains across our subscription business, and continued customer value delivered through our offerings,&#8221; said Craig Peters, CEO of Getty Images. 
&#8220;We remain committed to investing in the core assets of our company and continuing to evolve our offering in ways that deepen our relevance for our customers. We believe this strategy positions us well to achieve our 2025 outlook and beyond.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">NuScale Power Reports Q1 Results: Details</a>
Guidance: Getty raised its full-year 2025 revenue guidance from a range of $918 million to $955 million to a new range of $931 million to $968 million. Analysts are forecasting full-year revenue of $942.67 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Getty Images noted that it continues to work cooperatively with the U.S. Department of Justice and other non-U.S. regulators to obtain regulatory clearance for its proposed merger with Shutterstock.
GETY Price Action: <a href="http://benzinga.com/quote/gety">Getty Images shares</a> were down 1.99% in after-hours, trading at $1.97 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/brodogg1313">Eric Broder Van Dyke</a>/Shutterstock.

Guidance

After-Hours Center

Movers

Media

GETY

Getty Images Reports Q1 Results Below Estimates, Raises FY25 Guidance, Shares Slide

SK Telecom Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKM#NYSE">SKM</a>) reported quarterly earnings of $0.65 per share. This is a 4.41 percent decrease over earnings of $0.68 per share from the same period last year. The company reported $3.07 billion in sales this quarter. This is a 8.80 percent decrease over sales of $3.37 billion the same period last year.

SK Telecom Co Q1 EPS $0.65 Down From $0.68 YoY, Sales $3.07B Down From $3.37B YoY

eXoZymes Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) reported quarterly losses of $(0.22) per share. This is a 37.5 percent decrease over losses of $(0.16) per share from the same period last year.

EXOZ

eXoZymes Inc. - Common Stock Q4 EPS $(0.22) Down From $(0.16) YoY

Management

PROV

Provident Financial Holdings Appoints Peter C. Fan As  Chief Financial Officer, Effective May 12, 2025

Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) reported quarterly earnings of $0.01 per share. This is a 105.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $135.00 thousand in sales this quarter. This is a 33.52 percent decrease over sales of $203.06 thousand the same period last year.

OMEX

Odyssey Marine Explr Q1 EPS $0.01 Up From $(0.18) YoY, Sales $135.00K Down From $203.06K YoY

Barclays analyst Ramsey El-Assal maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Equal-Weight and raises the price target from $4 to $5.

Barclays Maintains Equal-Weight on Marqeta, Raises Price Target to $5

Paramount Gold Nevada (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PZG#AMEX">PZG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year.

Earnings Misses

Paramount Gold Nevada Q3 GAAP EPS $(0.04) Misses $(0.02) Estimate

Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.49) by 10.07 percent. This is a 7.34 percent increase over losses of $(1.77) per share from the same period last year.

BHVN

Biohaven Q1 Adj. EPS $(1.64) Misses $(1.49) Estimate

Barclays analyst Theresa Chen maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Overweight and raises the price target from $141 to $159.

Barclays Maintains Overweight on Marathon Petroleum, Raises Price Target to $159

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 10 years by 7.47% on an annualized basis producing an average annual return of 18.06%. Currently, Sprouts Farmers Market has a market capitalization of $15.34 billion. 
Buying $100 In SFM: If an investor had bought $100 of SFM stock 10 years ago, it would be worth $522.60 today based on a price of $156.71 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747085424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Barclays analyst Ramsey El-Assal maintains MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Equal-Weight and raises the price target from $14 to $16.

MARA

Barclays Maintains Equal-Weight on MARA Holdings, Raises Price Target to $16

WIIM

COIN

Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19.

Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/g45361621/microvast-reports-first-quarter-2025-financial-results">details from the quarter. </a>
The Details: Microvast reported adjusted earnings of six cents per share. Quarterly revenue of $116.5 million beat the Street estimate of $103.75 million and is an increase of 43.2% compared to $81.4 million from the prior year&#8217;s quarter.
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
For the first quarter, Microvast reported
<ul class="wp-block-list">
<li>Non-GAAP adjusted gross margin increased to 37%, up from 22.6% last year. </li>
<li>Non-GAAP adjusted operating expenses of $24.9 million, compared to $30.1 million in the first quarter of 2024.</li>
<li>Non-GAAP adjusted net profit of $19.3 million, compared to non-GAAP adjusted net loss of $13 million in the first quarter of 2024.</li>
</ul>
&#8220;Building on our strong momentum from 2024, Microvast delivered exceptional first quarter results, achieving record first quarter revenue of $116.5 million, a significant 43.2% year-over-year increase. This impressive top-line growth is coupled with a substantial expansion in gross margin to 36.9%,&#8221; said Yang Wu, Microvast&#8217;s CEO.
&#8220;For the quarter, we booked a net profit of $61.8 million and a positive adjusted EBITDA of $28.5 million, underscoring the increasing demand for our advanced battery solutions and the effectiveness of our focus on profitability and operational efficiency,&#8221; Wu added.
Outlook:&nbsp;Microvast maintained its previous guidance for the remainder of 2025 with target revenue growth of 18% to 25% year-over-year and revenue guidance of $450 million to $475 million. 
MVST Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Microvast stock was up 10.44% at $2.64 after-hours Monday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Tech

MVST

Microvast Stock Rallies After Q1 Results: Here's Why

Proceeds from the offering of senior unsecured notes to be used to redeem $993 million 7.625% senior unsecured notes due 2026&nbsp;
MIAMI, May 12, 2025 /PRNewswire/ --&nbsp;Carnival Corporation &amp;&nbsp;plc ((NYSE/LSE: CCL, NYSE:<a href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) today announced that Carnival Corporation (the "Company") priced its private offering (the "Notes Offering") of $1.0 billion aggregate principal amount of 5.875% senior unsecured notes due 2031 (the "Notes"). The Company expects to use the net proceeds from the Notes Offering to redeem the Company's $993 million 7.625% senior unsecured notes due 2026 (the "2026 Unsecured Notes").
The Notes Offering and the redemption of the 2026 Unsecured Notes are a continuation of the Company's strategy to reduce interest expense and manage its future debt maturities. The Company expects to reduce net annual interest expense by over $20 million through the scheduled maturity date of the 2026 Unsecured Notes as a result of the transaction and its partial redemption of $350 million of the 2026 Unsecured Notes earlier this year. In addition, the indenture that will govern the Notes will have investment grade-style covenants.
The Notes Offering is expected to close on May 21, 2025, subject to customary closing conditions. The previously announced redemption of the 2026 Unsecured Notes is expected to occur on May 22, 2025, and is conditioned on the closing of the Notes Offering.
The Notes will pay interest semi-annually on June 15 and December 15 of each year, beginning on December 15, 2025, at a rate of 5.875% per year. The Notes will be unsecured and will mature on June 15, 2031. The Notes will be fully and unconditionally guaranteed on an unsecured basis, jointly and severally, by Carnival plc and certain of the Company's and Carnival plc's subsidiaries that also guarantee our first-priority secured indebtedness, certain of our other unsecured notes and our convertible notes.

Offerings

Carnival Corporation Announces Pricing Of $1B 5.875% Senior Unsecured Notes Offering For Refinancing And Interest Expense Reduction

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call

Fortrea Named a Leader in Everest Group's Pharmacovigilance Operations PEAK Matrix® Assessment 2025

Fortrea Announces CEO Stepping Down

Fortrea Reports First Quarter 2025 Results

Small Cap

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Sotera Health

Stevanato Group

Alpha Teknova

10x Genomics

Barclays

Mizuho

Evercore ISI Group

Goldman Sachs

Citigroup

FTRE stock has given up its prior gain. Fortrea Holdings shares were trading higher after the company reported better-than-expected Q1 financial results.

Comments

Fortrea Holdings

뉴스

파트너 / 기고자

벤징가 글로벌